

esmo.org

ESMO Advanced Course on Early Drug Development Programme

ESMO Advanced Course

SINGAPORE 24-25 FEBRUARY 2023

Chairs

Jayesh Desai, Australia Elena Garralda, Spain Brigette Ma, Hong Kong

ESMO ADVANCED COURSE PROGRAMME EARLY DRUG DEVELOPMENT

Singapore 24-25 February 2023

CO-CHAIRS	Jayesh Desai, Australia Elena Garralda, Spain Brigette Ma, Hong Kong	SPEAKERS	Johanna Bendell, Switzerland Boon-Cher Goh, Singapore Josh C. C. Lin, Taiwan Do-Youn Oh, Korea Ruth Plummer, United Kingdom Toshio Shimizu, Japan Lillian L. Siu, Canada Anastasios Stathis, Switzerland Daniel S. W. Tan, Singapore Ben Tran, Australia Timothy A. Yap, United States
------------------	--	----------	--

LEARNING OBJECTIVES

- To foster, educate, and mentor the next generation of Phase I/Early Drug Development Programmes in Oncology centres from both the established and emerging economies in the Asia-Pacific region
- To understand the fundamentals of establishing and running a successful Phase I/Early Drug Development Programme: from an in-depth understanding of trial selection to patient coordination, to running a programme, to effectively engaging with sponsors and fellow PIs, to regional and international engagement, and regulatory processes
- To bridge the gap between the key stakeholders in the drug development process in the Asia-Pacific region: investigators, sponsors (Pharma and Biotech), Contract Research Organization (CRO), regulatory bodies

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from







ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4, 6900 Lugano, Switzerland Email: courses@esmo.org www.esmo.org



Friday, 24 February 2023

09:00-09:10	Welcome and course overview Jayesh Desai, AU, Elena Garralda, ES and Brigette Ma, HK	
09:10-10:40	Session 1 - Phase I clinical trial design & methods Co-Chairs: Jayesh Desai, AU and Elena Garralda, ES	
25'	Importance of phase I trials in drug development: Historical perspective Lillian L. Siu, CA	
25'	Current designs of phase 1 clinical trials Ruth Plummer, UK	
25'	Limitation of current designs and future designs Josh C. C. Lin, TW	
15'	Discussion & Survey Faculty	
10:40-11:10	Coffee break	
11:10-12:40	Session 2 - Step-by-step development of specific classes of drugs, patient selection, relevant biomarkers and pharmacodynamics Co-chairs: Elena Garralda, ES and Brigette Ma, HK	
25'	Targeted therapy, biomarkers, combinatorial approach Do-Youn Oh, KR	
25'	Immunotherapy, biomarkers, combinational approach Daniel S. W. Tan, SG	
25'	Other agents: e.g. drug conjugates, hormonal agents, cell-based therapies, Anastasios Stathis, CH	
15'	Discussion Faculty	
12:40-13:40	Lunch	
13:40-15:30	Session 3 - Patient selection, response & toxicity assessment Co-chairs: Jayesh Desai, AU and Brigette Ma, HK	
25'	Patient selection: Genomic matching to phase I trials, NGS, ctDNA, existing programmes Timothy A. Yap, US	
25'	Safety and adverse events management Ben Tran, AU	
25'	Assessing efficacy in novel phase I trials Toshio Shimizu, JP	
25'	Ethnic differences in drug tolerance and response Boon-Cher Goh, SG	
10'	Discussion Faculty	
15:30-16:00	Coffee break	

16:00-17:30	Session 4 - Practical & Operational Aspects Co-chairs: Elena Garralda, ES and Brigette Ma, HK
25'	Principal investigator's perspective: Assessing protocol, logistics, budget, resource allocation, phase I centres or site- based trials units? Jayesh Desai, AU
25'	Industry's perspective: Challenges, how to assess a site, metrics Johanna Bendell, CH
25'	Challenges: Facing Covid-19 and lessons learnt Jayesh Desai, AU, Elena Garralda, ES and Brigette Ma, HK
15'	Discussion Faculty
18:00	Networking dinner

Saturday, 25 February 2023

09:00-12:30	Workshop sessions Three parallel workshops sessions with around 20 delegates in each group (Delegates will attend all workshop sessions on a rotational basis) 10' Introduction based on clinical cases presented by speakers 45' Discussion 5' Break
Workshop 1 60'	 Meet your mentor: Building a career in Developmental Therapeutics Workshop leaders to discuss the following topics: Investigator-initiated trials and maximizing translational opportunities, publishing papers in phase I, developing a reputation as a phase I investigator, working in and with Pharma/Biotech, challenges in Covid-19 times, special issues for Asian-Pacific region, women/minorities related issues Mentoring junior faculties and building the workforce Mentor: Johanna Bendell, CH
Workshop 2 60'	 Becoming a phase I manager: Evaluating the Phase I package Understanding the pre-clinical science, pre-clinical toxicity, pearls and pitfalls, starting dose, dose selection, pharmacology/pharmacodynamics The decision-making process: Consider some case studies to highlight Mentor: Elena Garralda, ES Mentor: Ben Tran, AU
Workshop 3 60'	 Building a Phase I network in the Asia-Pacific (AP) region Experience in AP region of consortium: Pros & Cons Special tumour sites in AP region: How to attract sponsorship Mentor: Brigette Ma, HK Mentor: Jayesh Desai, AU
11:00-11:30	Coffee break
11:30-12:30	Workshop continuation
12:30-13:00	Feedback on the workshops/Results of survey
13:00-13:10	Conclusions Jayesh Desai, AU, Elena Garralda, ES and Brigette Ma, HK
13:10-14:10	Lunch